News Release
| Warner Chilcott Acquires P&G's Global Pharmaceuticals Business |
 |
P&G Focuses on Winning in Consumer Health Care To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/pg/39814/ (Logo: http://www.newscom.com/cgi-bin/prnh/20090115/CLTH035LOGO-a ) Under the terms of the agreement, "The acquisition of the P&G pharmaceutical brands and employee talent is a
transformational, strategic move for us," said "This move enables us to focus singularly on winning in consumer health
care - Personal Health Care, Oral Care and Feminine Care," said McDonald extended special thanks to P&G's pharmaceuticals employees. "These men and women have built a large and profitable global business which has improved millions of lives," he said. "Their welfare was a key consideration in the choice of a buyer. We are deeply grateful to them and are glad they'll be able to continue this work as part of another great company." P&G said it believes The sale of P&G's pharmaceuticals business to For Conference Calls P&G will host a conference call regarding this transaction on P&G Forward Looking Statements All statements, other than statements of historical fact included in this
release, are forward-looking statements, as that term is defined in the
Private Securities Litigation Reform Act of 1995. Such statements are based on
financial data, market assumptions and business plans available only as of the
time the statements are made, which may become out of date or incomplete. We
assume no obligation to update any forward-looking statement as a result of
new information, future events or other factors. Forward-looking statements
are inherently uncertain, and investors must recognize that events could
differ significantly from our expectations. In addition to the risks and
uncertainties noted in this release, there are certain factors that could
cause actual results to differ materially from those anticipated by some of
the statements made. These include: (1) the ability to achieve business plans,
including growing existing sales and volume profitably despite high levels of
competitive activity, especially with respect to the product categories and
geographical markets (including developing markets) in which the Company has
chosen to focus; (2) the ability to successfully manage ongoing acquisition
and divestiture activities to achieve the cost and growth synergies in
accordance with the stated goals of these transactions without impacting the
delivery of base business objectives; (3) the ability to successfully manage
ongoing organizational changes designed to support our growth strategies,
while successfully identifying, developing and retaining key employees; (4)
the ability to manage and maintain key customer relationships; (5) the ability
to maintain key manufacturing and supply sources (including sole supplier and
plant manufacturing sources); (6) the ability to successfully manage
regulatory, tax and legal requirements and matters (including product
liability, patent, intellectual property, competition law matters and tax
policy), and to resolve pending matters within current estimates; (7) the
ability to successfully implement, achieve and sustain cost improvement plans
in manufacturing and overhead areas, including the Company's outsourcing
projects; (8) the ability to successfully manage currency (including currency
issues in certain countries, such as Warner Chilcott Forward Looking Statements This press release contains forward-looking statements, including
statements concerning our operations, our economic performance and financial
condition, and our business plans and growth strategy and product development
efforts. These statements constitute forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. The words "may," "might," "will," "should,"
"estimate," "project," "plan," "anticipate," "expect," "intend," "outlook,"
"believe" and other similar expressions are intended to identify
forward-looking statements. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of their dates. These
forward-looking statements are based on estimates and assumptions by our
management that, although we believe to be reasonable, are inherently
uncertain and subject to a number of risks and uncertainties. The following
represent some, but not necessarily all, of the factors that could cause
actual results to differ from historical results or those anticipated or
predicted by our forward-looking statements: our substantial indebtedness;
competitive factors in the industry in which we operate (including the
approval and introduction of generic or branded products that compete with our
products); our ability to protect our intellectual property; a delay in
qualifying our manufacturing facility to produce our products or production or
regulatory problems with either third party manufacturers upon whom we may
rely for some of our products or our own manufacturing facilities; pricing
pressures from reimbursement policies of private managed care organizations
and other third party payors, government sponsored health systems, the
continued consolidation of the distribution network through which we sell our
products, including wholesale drug distributors and the growth of large retail
drug store chains; the loss of key senior management or scientific staff;
adverse outcomes in our outstanding litigation or an increase in the number of
litigation matters to which we are subject; government regulation affecting
the development, manufacture, marketing and sale of pharmaceutical products,
including our ability and the ability of companies with whom we do business to
obtain necessary regulatory approvals; our ability to manage the growth of our
business by successfully identifying, developing, acquiring or licensing new
products at favorable prices and marketing such new products; our ability to
obtain regulatory approval and customer acceptance of new products, and
continued customer acceptance of our existing products; changes in tax laws or
interpretations that could increase our consolidated tax liabilities; the
other risks identified in our Annual Report on Form 10-K for the year ended
We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law. About Three billion times a day, P&G brands touch the lives of people around the world. P&G has one of the strongest portfolios of quality, leadership brands in consumer health and wellness, including Align , Always , Crest , Metamucil , Oral-B , Pepto-Bismol , Prilosec OTC , Scope , Tampax , and Vicks , in addition to its trusted consumer brands, including Ariel , Braun , Bounty , Charmin , Dawn , Downy , Duracell , Gillette , Head & Shoulders , Iams , Lenor , Mach3 , Olay , Pantene , Pampers , Pringles , Tide , Wella , and Whisper . The P&G community consists of approximately 135,000 employees working in about 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands. About
SOURCE CONTACT: News Media, |
Touching lives, improving life. P&G™